Pfizer is one of the largest pharmaceutical companies worldwide and its commitment to healthcare can be seen through their various programs and their efforts to spread medicine worldwide.
In 2019 alone, they made two acquisitions to increase their drug pipeline – Therachon and Array Biopharma were acquired as key additions.
The Company’s Origins
Few companies exemplify the term “pharma giant” better than Pfizer. Established in New York by Charles Pfizer and Charles Erhart soon after their migration from Ludwigsburg, Germany to America in 1849, this American pharmaceutical and biotechnology company began as a fine chemicals business founded upon Pfizer’s chemical expertise while Erhart brought confectionary expertise. Early success came when its initial product, an antiparasitic drug known as Santonin (later Santonin salt) proved immensely popular with patients.
By the 1860s, Pfizer had grown substantially and employed over 300 people. Pfizer was propelled further forward during the American Civil War as it produced enormous quantities of antiseptics and painkillers for Union soldiers as well as citric acid, used as a remedy against scurvy. By 1900’s end, sales had exceeded $3 Million!
Pfizer first ventured into research-based pharmaceuticals during the early 1900s with a view toward creating treatments for various illnesses. They expanded globally too. Pfizer’s move into research and development represented a pivotal moment as its focus shifted away from manufacturing products to finding innovative solutions to medical challenges.
Pfizer continued its expansion throughout its first 30 years by way of acquisitions and partnerships, such as merging with Warner-Lambert in 2000, Pharmacia & Upjohn in 2002, Wyeth in 2009, and Medivation in 2016. These deals helped Pfizer increase market share across generic medications, consumer healthcare products, vaccines and vaccines.
By the dawn of the 21st century, Pfizer had become a global powerhouse with presence in over 160 countries. Additionally, they engaged in political lobbying activities which helped shape policies impacting its industry – an activity which sometimes generated controversy and led to lawsuits with multibillion-dollar settlement payments as a result.
Pfizer remains committed to revolutionizing healthcare through developing transformative medications that enhance global health and well-being. Their commitment to innovation and global health can be seen through their efforts to advance healthcare practices and meet critical medical needs around the globe.
Its Early Years
Pfizer, as one of the world’s premier research-based pharmaceutical and biomedical companies, is dedicated to improving global health outcomes while shaping medicine of tomorrow. Through an expansive pipeline of innovative therapies and an uncompromising commitment to patient care, the company strives to ensure patients access their medications quickly.
Charles Pfizer and Charles Erhart, two German immigrants living in Brooklyn, New York, founded their company in 1849 as a fine chemicals business producing anti-parasitic medications. By the time of American Civil War which saw a substantial surge in demand for painkillers disinfectants and pharmaceutical products becoming vital supplies of military healthcare units it had grown significantly to become one of the country’s major industrial chemical producers.
Pfizer chemists pioneered a process to mass produce citric acid through mold fermentation in the late 1800s, freeing the company from dependence on European citrus growers and leading them to manufacture numerous consumer and medical products such as ice cream, cola and dyes.
As its growth accelerated, Pfizer began making significant investments in research and development capabilities. Not only was the pharmaceutical giant creating its own drugs; but also acquired multiple other businesses to broaden its product offering and market reach.
At the close of the 20th century, Pfizer had reached its most diverse point ever in history, boasting subsidiaries producing everything from petrochemicals and animal health products to perfumes and dietary supplements. Meanwhile, revenue had reached record heights due to Paxlovid and Comirnaty vaccine sales totalling more than $37 billion combined.
Pfizer was known for the success of their products during this era; however, there were also challenges. Pfizer found itself subject to high-profile lawsuits concerning marketing practices as well as losing patent protection on many of their best-selling drugs. Furthermore, their efforts at using tax loopholes to avoid paying US taxes on foreign earnings proved controversial.
Pfizer persevered despite these setbacks to expand globally. Over this period, they made several major acquisitions such as Warner-Lambert in 2000; Pharmacia and Upjohn in 2002; Wyeth in 2009 and Medivation in 2016. In addition to increasing their global reach, Pfizer sought to enhance their research and development capabilities by investing in emerging markets, developing novel vaccines and acquiring companies with promising late stage development programs.
Its Growth
Pfizer has built its global presence through strategic acquisitions. In 1961 alone, Pfizer spent $130 million to buy 14 businesses ranging from vitamins manufacturers and animal antibiotics producers to chemicals suppliers and cosmetics producer Coty. This diversification laid the groundwork for what would later become one of the world’s multibillion-dollar pharmaceutical conglomerates.
One of Pfizer’s key breakthroughs occurred in 1941 when it accelerated production of penicillin for use by Allied soldiers fighting World War II. This marked the first time Pfizer used fermentation technology to mass produce drugs; additionally, they hired sales reps for promotion purposes for their products.
Pfizer continued its acquisition strategy over several decades to build its portfolio and remain competitive against other pharmaceutical firms.
Pfizer was an industry leader when it came to research and development of new drugs during the 2000s, producing several blockbuster medications such as Lipitor and Zoloft which became hugely successful, helping increase Pfizer’s revenue base significantly.
Pfizer made significant investments during this time in developing innovative medicines, including vaccines. Their new offerings included RSV vaccines as well as treatments for ulcerative colitis and migraines, in addition to increasing investments in biologics – an emerging area of pharmaceutical innovation.
Pfizer has struggled in recent years to sustain its growth momentum and overcome significant challenges related to patent expirations on several popular drugs like blood thinner Eliquis and cancer treatment Ibrance. Pfizer will face increased competition if these patents lapse.
The company also faces competition from copycat biosimilars, generic versions of biological drugs that are cheaper to produce than biologics. Copycats have quickly gained ground within the industry due to their relatively lower production costs.
Pfizer remains a titan in the industry despite facing challenges, having recently passed $100 billion in annual revenue due to strong results from its COVID-19 products (such as Comirnaty vaccine by BioNTech for $37.8 billion and Paxlovid selling $18.9 billion in sales).
Its Mergers and Acquisitions
Pfizer today is the result of numerous mergers and acquisitions as well as its extensive product pipeline, all which have combined to form one of the world’s largest pharmaceutical companies. Their biggest purchase was Warner Lambert in 2000 followed by Pharmacia and Wyeth acquisitions.
Company officials note that they have also made several smaller deals that have helped it thrive in modern times. For example, in 2015 they attempted to acquire UK firm AstraZeneca for $100 billion, an action which caused widespread controversy as it used tax loopholes to avoid paying US taxes on profits earned overseas and circumvent new legislation passed under President Obama.
Pfizer made history again when they announced they would acquire biotech firm Seagen for $43 billion, in one of the biggest acquisitions ever undertaken by any corporation in modern times. Not only was this deal hugely significant for Pfizer but it marked a shift in its business approach: M&A no longer served solely as an avenue to gain market share but was seen more as an opportunity to bring new products more quickly to market.
As part of its ongoing dedication to healthcare, Pfizer has invested in research facilities and institutes around the globe as part of its ongoing commitment. They offer fellowship programs and internships for aspiring pharmaceutical professionals. Pfizer has long been recognized for revolutionizing global healthcare landscape with life-changing medicines delivered around the globe; regardless of setbacks they remain committed to their mission of improving people’s lives wherever possible – an ode to its founders’ vision as well as unwavering innovation commitment.
